These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37195698)

  • 41. A primer on economic evaluations related to expansion of newborn screening for genetic and metabolic disorders.
    Hubbard HB
    J Obstet Gynecol Neonatal Nurs; 2006; 35(6):692-9. PubMed ID: 17105633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
    Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic testing: an economic and contractarian analysis.
    Tabarrok A
    J Health Econ; 1994 Mar; 13(1):75-91. PubMed ID: 10134440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England.
    Williams J; Miners A; Harris R; Mandal S; Simmons R; Ireland G; Hickman M; Gore C; Vickerman P
    Value Health; 2019 Nov; 22(11):1248-1256. PubMed ID: 31708061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The need for a science of community genetics.
    Modell B
    Birth Defects Orig Artic Ser; 1992; 28(3):131-41. PubMed ID: 1489951
    [No Abstract]   [Full Text] [Related]  

  • 46. Recent economic evaluations of antenatal screening: a systematic review and critique.
    Petrou S; Henderson J; Roberts T; Martin MA
    J Med Screen; 2000; 7(2):59-73. PubMed ID: 11002445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis.
    Kahn R; Alperin P; Eddy D; Borch-Johnsen K; Buse J; Feigelman J; Gregg E; Holman RR; Kirkman MS; Stern M; Tuomilehto J; Wareham NJ
    Lancet; 2010 Apr; 375(9723):1365-74. PubMed ID: 20356621
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.
    Hoerger TJ; Harris R; Hicks KA; Donahue K; Sorensen S; Engelgau M
    Ann Intern Med; 2004 May; 140(9):689-99. PubMed ID: 15126252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of screening for HIV.
    da Silveira E
    N Engl J Med; 2005 May; 352(20):2137-9; author reply 2137-9. PubMed ID: 15906436
    [No Abstract]   [Full Text] [Related]  

  • 50. Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States.
    Choi H; Mohit B
    Epilepsia; 2019 Jul; 60(7):1472-1481. PubMed ID: 31158306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
    Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
    AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis.
    Hu D; Hook EW; Goldie SJ
    Ann Intern Med; 2004 Oct; 141(7):501-13. PubMed ID: 15466767
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Making a Genetic Diagnosis in a Level IV Neonatal Intensive Care Unit Population: Who, When, How, and at What Cost?
    Swaggart KA; Swarr DT; Tolusso LK; He H; Dawson DB; Suhrie KR
    J Pediatr; 2019 Oct; 213():211-217.e4. PubMed ID: 31255390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
    Chong HY; Lim YH; Prawjaeng J; Tassaneeyakul W; Mohamed Z; Chaiyakunapruk N
    Pharmacogenet Genomics; 2018 Feb; 28(2):56-67. PubMed ID: 29176400
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population screening for genetic disorders in the 21st century: evidence, economics, and ethics.
    Grosse SD; Rogowski WH; Ross LF; Cornel MC; Dondorp WJ; Khoury MJ
    Public Health Genomics; 2010; 13(2):106-15. PubMed ID: 19556749
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations.
    Di Marco M; DAndrea E; Panic N; Baccolini V; Migliara G; Marzuillo C; De Vito C; Pastorino R; Boccia S; Villari P
    Genet Med; 2018 Oct; 20(10):1131-1144. PubMed ID: 29300371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review.
    Rosso A; Pitini E; D'Andrea E; Massimi A; De Vito C; Marzuillo C; Villari P
    Ann Ig; 2017; 29(5):464-480. PubMed ID: 28715059
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
    Holmes J; Hemmett L; Garfield S
    Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
    J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of genomics on the future of medicine and health.
    Mattick JS; Dziadek MA; Terrill BN; Kaplan W; Spigelman AD; Bowling FG; Dinger ME
    Med J Aust; 2014 Jul; 201(1):17-20. PubMed ID: 24999876
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.